Should patients with hepatitis C genotype 2/3 infection who are slow responders to pegylated interferon/ribavirin have treatment duration extended?

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|62|2|660-661

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.62, Iss.2, 2015-08, pp. : 660-661

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Meta-Analysis: Superior Treatment Response in Asian Patients with Hepatitis C Virus Genotype 6 versus Genotype 1 with Pegylated Interferon and Ribavirin

By  

Intervirology, Vol. 58, Iss. 1, 2015-01 ,pp. : 27-34

Karger

Access to resources Recommend Favorite

Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection

By  

HEPATOLOGY, Vol. 270-9139, Iss. 4, 2015-10 ,pp. : 1013-1023

John Wiley & Sons Inc

Access to resources Recommend Favorite

Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection

By  

HEPATOLOGY, Vol. 62, Iss. 4, 2015-10 ,pp. : 1013-1023

John Wiley & Sons Inc

Access to resources Recommend Favorite

Add‐on effects of fluvastatin in simeprevir/pegylated‐interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study

By  

HEPATOLOGY RESEARCH, Vol. 48, Iss. 3, 2018-02 ,pp. : E146-E154

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long-term Re-treatment with Interferon and Ribavirin Combination Therapy in Patients with Chronic Hepatitis C who are Non-responders to Interferon Alone: a Preliminary Study

By Vega P.   Castro A.   Hermida M.   López Calvo S.   Pedreira J.  

Scandinavian Journal of Infectious Diseases, Vol. 31, Iss. 4, 1999-09 ,pp. : 359-361

Informa Healthcare

Access to resources Recommend Favorite